Quantcast

Charting a TRP to Novel Therapeutic Destinations for Kidney Diseases.

Research paper by Juan Lorenzo JL Pablo, Anna A Greka

Indexed on: 21 May '21Published on: 11 Nov '19Published in: Trends in Pharmacological Sciences



Abstract

Ion channels are critical to kidney function, and their dysregulation leads to several distinct kidney diseases. Of the diversity of ion channels in kidney cells, the transient receptor potential (TRP) superfamily of proteins plays important and varied roles in both maintaining homeostasis as well as in causing disease. Recent work showed that TRPC5 blockers could successfully protect critical components of the kidney filter both in vitro and in vivo, thus revealing TRPC5 as a tractable therapeutic target for focal and segmental glomerulosclerosis (FSGS), a common cause of kidney failure. Human genetics point to three additional TRP channels as plausible therapeutic targets: TRPC6 in FSGS, PKD2 in polycystic kidney disease, and TRPM6 in familial hypomagnesemia with secondary hypocalcemia (HSH). We conclude that targeting TRP channels could pave the way for much needed therapies for kidney diseases. Copyright © 2019 Elsevier Ltd. All rights reserved.